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Abstract 
Objective: Chronic obstructive pulmonary disease (COPD) is 
characterized by systemic inflammation and accelerated inflammaging 
of the lungs. Some studies showed that conjugated linoleic acid (CLA) 
has anti-inflammatory effects. The aim of the present study was to 
evaluate the effect of CLA supplementation on serum levels of 
interleukin (IL)-6 and sirtuin1 (SIRT1) in patients with COPD. 
Materials and Methods: 82 patients with stable COPD were 
enrolled in a double blind clinical trial. Subjects were randomly 
assigned to two groups: placebo (n=42) and 3.2 g CLA daily 
supplementation (n=40). Forced expiratory volume in one second 
(FEV1%), BODE index, and serum levels of IL-6, and SIRT1 were 
measured at the baseline and six weeks after the intervention. In 
addition, the study parameters in the two groups were compared 
based on the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) criteria. 
Results: After supplementation with CLA, serum levels of IL-6 and 
BODE index significantly decreased (p<0.05 and p<0.001, 
respectively). In addition, serum levels of SIRT1 (p<0.01) and 
FEV1 (p<0.001) significantly increased in the supplementation 
group. Based on GOLD criteria, the increase in SIRT1 and the 
decrease in IL-6 serum levels were found to be statistically 
significant in stages III and IV in the supplementation group 
(p<0.05 and p<0.01, respectively) 
Conclusion: Supplementation with CLA can modify the 
inflammatory markers and improve the health status of COPD 
patients. The results suggest that CLA supplementation in COPD 
patients can be useful in the management of the disease.
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Introduction 
Chronic obstructive pulmonary disease 
(COPD) is the third leading cause of death 
in the world, resulting in more than 3 
million deaths by 2020 (Andersen et al., 
2011). It is estimated that in the next 10 
years, COPD deaths will increase by 30% if 
there is no preventive action (Chun, 2015). 
The main feature of COPD is the airflow 
limitation, which is usually progressive and 
is associated with the chronic inflammatory 
response of the airways to gases and 
noxious particles (McDonough et al., 
2011). Important factors in the 
pathogenesis of COPD are airway 
inflammation, protease-antiprotease 
imbalance and oxidative stress (Fischer et 
al., 2011). COPD not only primarily affects 
the lungs, but is also associated with a low-
grade chronic systemic inflammation 
(Amani et al., 2017). In the peripheral blood 
of patients with COPD, elevated levels 
inflammatory mediators such as interleukin 
(IL)-6, IL-1β, tumor necrosis factor-alpha 
(TNF-α), and C-reactive protein (CRP) 
were shown (Gan et al., 2004; Ghobadi et 
al., 2017). IL-6 is a strong stimulus for 
production of CRP and plays a key role in 
the pathophysiology of malnutrition of 
COPD patients (Ferrari et al., 2013). Also, 
in the development of systemic 
inflammation in COPD, various factors, 
including adipocytes, are involved (Zhang 
et al., 2016). In the pulmonary 
inflammatory process, it was reported that 
adipocytokines have a key role in airway 
inflammation (Aslani et al., 2016a; Aslani 
et al., 2016b). Some studies showed that 
various adipocytokines such as leptin, 
adiponectin, and visfatin are candidate 
biomarkers for lung inflammatory diseases 
(Aslani et al., 2017; Keyhanmanesh et al., 
2018). 
The progress of symptom in COPD 
patients is slow and is generally seen in 
elder population (Ito and Barnes, 2009). 
Accordingly, considerable evidence 
emphasizes accelerated aging in the lungs 
of COPD patients (Ito and Barnes, 2009; 
Yanagisawa et al., 2017). Many aging 
characteristics are evident in patients with 
COPD including mitochondrial 
dysfunction, cellular senescence, stem cell 
lost, impaired autophagy, and a low-grade 
chronic inflammation (Carollo et al., 2018). 
Under oxidative stress conditions, 
accelerated aging may result in a defective 
performance of some endogenous antiaging 
molecules such as sirtuins (Barnes, 2016). 
Sirtuins are a family of highly conserved 
protein deacetylases and their activity 
depends on nicotinamide adenine 
dinucleotide (Carollo et al., 2018). Sirtuin 1 
(SIRT1) is a one of the most important 
sirtuins that protects cells from cellular 
damage caused by oxidative stress, and 
increases health and life duration (Carollo 
et al., 2018). Growing evidence suggests 
that SIRT1 levels are reduced in COPD 
patients, and they have a positive 
correlation with the severity of disease 
(Yanagisawa et al., 2017).  
Development of an effective treatment 
for patients with COPD remains a 
challenge. The use of other therapies, 
especially dietary supplementation, is a 
clinical requirement for patients with 
COPD. Conjugated linoleic acids (CLA) is 
lipid derived from fatty acid of ruminant 
animals and it attracted attentions for its 
effects on obesity, insulin sensitivity and 
body composition (Chin et al., 1992). It was 
identified that feeding of animals with 
plants such as soybean and sunflower 
increases the level of CLA in their milk fat. 
There are many biological effects for CLA 
including effects on atherosclerosis, 
carcinogenesis and immune modulation 
(Kelley et al., 2007; O'Shea et al., 2004). In 
a randomized placebo-controlled trial in 
subjects with COPD, we previously showed 
that CLA supplementation reduced serum 
levels of IL-1β (Ghobadi et al., 2016).  
Although there are many studies about 
cellular mechanisms underlying the effects 
of CLA supplementation on pro-
inflammatory and oxidative stress markers, 
few clinical trials were conducted to show 
its effects on inflammatory markers in 
patients with COPD. Accordingly, the 
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present study was designed to investigate 
the preventive effect of six-week treatment 
of CLA supplementation on the modulation 
of the serum concentrations of IL-6 and 
SIRT1, exercise tolerance and pulmonary 
function test (PFT) in patients with COPD.  
 
 
Materials and Methods 
In the present double-blind clinical trial 
study, 93 patients with stable COPD were 
recruited from April 2015 to December 
2015. All patients were male and COPD 
was diagnosed according to the American 
Thoracic Society (ATS) guidelines (Vestbo 
et al., 2013). The inclusion and exclusion 
criteria were fully addressed previously 
(Amani et al., 2017). Briefly, under 
standard conditions, pulmonary function 
testing was performed using spirometry 
(Chest Inc., 801, Tokyo, Japan) based on 
ATS guidelines. Pulmonary function and 
biochemical tests were conducted on the 
same day for COPD and control subjects. 
Eleven patients were excluded from study 
analysis due to exclusion criteria. 
Eventually, 82 patients completed the study 
(42 patients in the placebo and 40 patients 
in the supplementation groups) (Figure 1). 
 
Figure 1. The effect of CLA-supplementation on the serum level of IL-6 and sirtuin-1 in COPD patients. 
 
The GOLD guidelines were used to 
categorize the severity of COPD and the 
six-minute walk distance (6MWD) was 
performed according to the guidelines of 
the ATS (Laboratories, 2002). Finally, we 
used the model described by Celli et al. to 
calculate BODE index (Celli et al., 2004).  
This study is the final process of a 
clinical trial that was previously reported 
the effect of CLA on IL-1β and MMP 
(Ghobadi et al., 2016). In the intervention 
group, patients received a soft gel capsule 
containing 3.2 g of CLA. Capsules contain 
c9-t11 and c12-t10 isomers made by Nortex 
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Company (Nutrex Reaserch Inc., Oviedo, 
FL, USA) under the brand name Nortex. 
The intervention duration was 6 weeks and 
the control group received the same amount 
of placebo. To create double-blind 
conditions, at the beginning of the study, 
containers containing placebo and 
intervention capsules were coded with the 
letters A and B and the interviewers and 
patients were not aware of the contents of 
the containers. 
The study was approved by Ardabil 
University of Medical Sciences Ethics 
Committee (IR.ARUMS.REC.1396.79), 
and all of the study participants signed 
written consent forms and the trial was 
registered in Iranian Registry of Clinical 
Trial “IRCT2015080823559N1”. 
 
Biochemical measurements 
Approximately 3-5 ml of blood samples 
were taken from all patients to determine 
serum levels of SIRT1 and IL-6 before and 
after intervention. Serum IL-6 (BE53061; 
IBL International, Hamburg, Germany) and 
SIRT1 (Hangzhou Eastbiopharm Co. Ltd., 
catalog: E20180511) levels were measured 
using a commercial kit. The results were 
reported as pg/ml. 
Statistical analysis 
Continuous variables were evaluated for 
normal distribution by the Shapiro-Wilk 
test. The results are given as the mean±SD 
(or median and 25th–75th percentiles). 
Data with normal distribution in the two 
study groups were compared using the t-test 
or the Wilcoxon‐Mann‐Whitney test for 
data with a skewed distribution. In order to 
calculate the percentage change of variables 
during the study period, the following was 
performed: (Value after treatment – value 
before treatment) / value before treatment X 
100. A value of p<0.05 was considered 
significant. 
 
 
Results 
Table 1 shows baseline variables for the 
two groups. There was no statistically 
significant difference in terms of age, 
pack/year, BMI, FEV1, FVC, FEV1/FVC, 
BODE, 6MWD, IL-6, and SIRT1 at the 
onset of the study between the two groups 
(p>0.05) (Table 1). 
  
Table 1. Baseline parameters in each group. 
 
 
Variables 
Placebo (n=42) CLA (n=40)  
P-Value Baseline Baseline 
Age 
Pack/year 
BMI 
FEV1 (%) 
FVC (%) 
FEV1/FVC ratio 
6MWT 
mMRC 
BODE index 
IL-6 (pg/ml) 
SIRT1 (pg/ml) 
61.55±10.81 
45.71±26.11 
24.84±3.06 
40.27±15.09 
56.69±17.77 
57.13±8.66 
335.79±190.89 
2.36±0.54 
4.05±1.92 
4.05 (3.14-5.24) 
15.30 (12-17.60) 
63.82±10.58 
43.40±25.11 
25.46±3.85 
46.14±17.80 
65.93±18.84 
56.29±9.86 
397.92±141.50 
2.58±0.54 
4.22±1.88 
3.83 (2.60-4.82) 
11.75 (6.30-16.90) 
0.338 
0.684 
0.426 
0.111 
0.049 
0.684 
0.099 
0.084 
0.675 
0.489 
0.100 
 
BMI: body mass index, FEV1: Forced expiratory volume in 1 second, FVC: Forced vital 
capacity, BODE: (BMI, Airway obstruction, Dyspnea, Exercise tolerance)-index, 6MWT:  6-
minute walk distance, mMRC: Modified Medical Research Council, BODE: (BMI, Airway 
obstruction, Dyspnea, Exercise tolerance) index, IL-6: interleukin-6, SIRT1: sirtuin 1. 
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Effects of CLA supplementation on 
pulmonary function test, and IL-6 and 
SIRT1 serum levels 
No statistically significant differences 
were observed in serum levels of IL-6 
(Figure 3a) and SIRT1 (Figure 3b) in the 
placebo group when baseline and after 
intervention data were compared. However, 
pulmonary function test results showed that 
FEV1% predict (p<0.001) (Figure 2a) 
significantly decreased during the study 
period in the placebo group. On the other 
hand, compared to baseline values, a 
significantly increased pulmonary function 
test of FEV1% predict (46.14±17.80 vs. 
49.65±17.44, p<0.001) (Figure 2a) was 
found after treatment with CLA in 
supplementation group. BODE index 
results showed a significant decrease in the 
CLA group compared to placebo group 
(p<0.001, Figure 2b). Also, intervention 
with CLA was found to significantly 
decrease IL-6 (4.43±2.77 vs. 3.40±2.32, 
p<0.01) and increase SIRT1 levels 
(13.84±10.59 vs. 18.60±8.79, p<0.01).  
In the supplementation group, compared 
to the placebo group, there was a 
statistically significant decrease in 
percentage change of IL-6 (p<0.01) and 
BODE score (p<0.001, Table 2). In 
addition, the percentage change of FEV1 
(p<0.001), FEV1/FVC ratio (p<0.001), 
6MWD (p<0.001), and SIRT1 (p<0.05) 
were significantly higher than those of the 
placebo group (Table 2). 
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Figure 2. FEV1% predict (a) and BODE index (b) at baseline and after treatment period in placebo and CLA 
supplementation groups. Data are shown as individual value (for FEV1%) and mean±SD (or median and 25th–
75th percentiles) values of percent changes in FEV1% predict (c) and BODE index (d) based on GOLD criteria 
in placebo and CLA supplementation groups during the study period. FEV1; forced expiratory volume in 1 second, 
BODE index; (Body mass index, airflow Obstruction, Dyspnea and Exercise capacity).*: p<0.05, **: p<0.01, and 
***: p<0.001. 
 
Based on the GOLD criteria, it was 
found that in the CLA group, value of 
changes in FEV1 were increased both in 
GOLD I and II (3.41±2.57% vs -
0.48±4.07%, p<0.05) and GOLD III and IV 
phases (3.55±3.72% vs -2.34±4.32%, 
p<0.001) when compared with placebo 
group (Figure 2c). Also, BODE index 
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change values between CLA and placebo 
groups showed a decrease in both GOLD I-
II (-1.33±1.84% vs 0.00±0.00%, p<0.01) 
and GOLD III-IV phases (-1.18±0.58% vs 
0.37±1.33%, p<0.001) (Figure 2d). 
However, the comparison of IL-6 and 
SIRT1 levels after intervention with CLA 
showed a significant decrease in IL-6 
(p<0.01, Figure 3c) and an increase in 
SIRT1 (p<0.05, Figure 3d) only in stages 
III-IV of GOLD criteria.  
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Figure 3. Serum levels of IL-6 (a) and SIRT1 (b) at baseline and after treatment period in placebo and CLA 
supplementation groups. Data are shown as mean±SD (or median and 25th–75th percentiles) values of percent 
changes in serum IL-6 (c) and SIRT1 (d) based on GOLD criteria in placebo and CLA supplementation groups 
during the study period.  IL-6; interleukin 6, and SIRT1: sirtuin-1. *: p<0.05, **: p<0.01, and ***: p<0.001  
 
Table 2. Percent change in different parameters after treatment period relative to baseline values 
variables Placebo (n=42) CLA (n=40) P value 
FEV1 (%) 
 
FVC (%) 
 
FEV1/FVC ratio 
 
6MWD 
 
BODE index 
 
IL-6 (pg/mL) 
 
SIRT1 (pg/mL) 
 
-1.89±4.29 
(-4.92%) 
-0.009±5.86 
(1.24%) 
-0.86±5.10 
(-1.27%) 
-4.97±41.29 
(0.65%) 
0.28±1.17 
(11.72%) 
0.35±2.20 
(15.05%) 
0.53±11.92 
(5.95%) 
3.50±3.22 
(9.30%) 
-2.01±10.74 
(-0.33%) 
5.06±7.28 
(10.26%) 
33.82±31.24 
(15.76%) 
-1.25±1.29 
(-29.55%) 
 -1.03±2.40 
(-11.97%) 
4.76±9.58 
(21.50%) 
0.000 
 
0.010 
 
0.000 
 
0.000 
 
0.000 
 
0.004 
 
0.025 
FEV1: Forced expiratory volume in 1 second, FVC: Forced vital capacity, 6MWT:  6-minute walk distance, 
BODE: (BMI, Airway obstruction, Dyspnea, Exercise tolerance) index, IL-6: interleukin-6, and SIRT1: sirtuin 1. 
Discussion 
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The effect of CLA supplementation (3.2 
g/day) in a six-week study period, was 
tested on pulmonary function test, GOLD 
stage, IL-6, and SIRT1 in patients with 
COPD.  
The results of the present clinical trial 
indicated that CLA supplementation 
significantly reduced serum level of IL-6 
and BODE index. In addition, CLA led to 
elevated serum levels of SIRT1, PFT and 
6MWD compared to baseline values and 
the placebo group. However, none of these 
effects were seen in the placebo group.    
Our results showed that CLA 
supplementation had clinical effects on 
patients with COPD by improving FEV1 
and FEV1/FVC. In fact, in the 
supplementation group, the percentage of 
improvement in pulmonary function test 
was significantly higher than those of the 
baseline and the placebo group. Therefore, 
it can be concluded from the results of the 
study that CLA supplementation has 
preventive therapeutic effects in COPD 
patients. Interestingly, according to the 
results of the GOLD stage, it was found that 
the effects of CLA on increment of FEV1 
value were significant at stages III and IV. 
From the results of MacRedmond et al. 
study, it is evident that CLA 
supplementation increases PFT in 
asthmatic patients (MacRedmond et al., 
2010). Evidence suggests that CLA is able 
to produce clinically significant reductions 
in hyper-reactivity and airway 
inflammation by affecting adipocytokines, 
growth factors, inflammatory mediators, 
immunoglobulin, and lipid mediators 
(MacRedmond et al., 2010).  
High serum levels of IL-6, IL-8, IL-1β 
and TNF-α were seen in patients with 
COPD, which actually represents systemic 
inflammation (Wouters et al., 2007). In the 
pathogenesis of COPD, IL-6 and IL-8 play 
a key role in stable and exacerbation 
condition (Knobloch et al., 2010). Also, in 
some human studies, it was shown that 
increased IL-6 is associated with 
pulmonary impairment in patients with 
COPD (Wei et al., 2015).  By affecting liver 
cells, IL-6 can act as a crucial cytokine in 
the production of a variety of acute phase 
proteins such as CRP and fibrinogen (Wei 
et al., 2015). It was shown that even stable 
COPD patients have high levels of CRP, 
leukocytes, fibrinogen and platelets (Sin 
and Man, 2008). IL-6 plays an active role 
by attracting neutrophils to the airways, as 
well as regulating several pathways 
involved in the progression of inflammation 
in the airways (Ferrari et al., 2013). 
Although the precise mechanism of IL-6 
action in lung tissue destruction is not clear, 
it is imagined that IL-6 by tissue deposition, 
and producing protease and antibody 
complexes, causes destruction of lung 
tissue (Ferrari et al., 2013).  
In this study, CLA supplementation 
resulted in a decrease in IL-6 serum levels, 
while no significant changes were observed 
in the placebo group. We also found that 
CLA supplementation results in a 
significant increase in 6MWD and 
decreased the BODE score in the CLA 
supplementation group when compared 
with baseline value as well as the placebo 
group. It has been identified that there was 
an association between increase IL-6 and 
reduction of physical performance of 
COPD patients, although the causal relation 
is unclear (Ferrari et al., 2013). Brinkely et 
al. demonstrated that high levels of IL-6 
were associated with decreased physical 
activity in older adults with multiple 
comorbidities, such as COPD independent 
of age, race, sex, and body composition 
(Brinkley et al., 2009). Also, studies 
conducted by Garrod et al. and Yende et al. 
identified that there was a negative 
association between IL-6 levels and 6MWD 
in COPD patients (Garrod et al., 2007; 
Yende et al., 2006). In addition, Pinto-Plata 
et al. showed that high levels of 
inflammatory markers were associated with 
a degree of airflow limitation, health status 
and functional capacity (Pinto-Plata et al., 
2012).  
Based on our study, improvement in 
pulmonary function test and BODE score in 
the supplementation group was probably 
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due to a reduction in IL-6 levels. Research 
on food immunology in animal study has 
revealed an important role for the CLA 
regimen in reducing inflammation 
(Changhua et al., 2005). CLA 
supplementation was shown to be able to 
reduce levels of IL-6, IL-1β, and TNF-α 
and increase IL-10 levels (Changhua et al., 
2005). The inhibitory effects of CLA on the 
production of pro-inflammatory cytokines 
at the molecular level are likely to be 
dependent on transcriptional regulation. In 
animal studies, it was demonstrated that the 
modulatory effects of CLA in the synthesis 
of pro-inflammatory cytokines are 
dependent on the PPARγ mechanism 
(Changhua et al., 2005). As a result of 
activation of PPARγ, down-regulation 
occurs in the signal pathways of mitogen 
activated protein kinase (MAPK) and 
nuclear factor-κB (NF-kB) (Changhua et 
al., 2005). CLA, possibly with its anti-
inflammatory effects, was able to exert 
improving effects in patients with COPD. 
However, it should be noted that IL-6 is 
produced by various cells and organs in 
patients with COPD such as the liver, 
muscle, adipocytes, and lung (Sin and Man, 
2008), and the effects of CLA on reducing 
the amount of circulating IL-6 require 
further studies. 
We also indicated that the protein level 
of SIRT1 in CLA supplementation group 
was increased compared to baseline and 
placebo group, whereas in placebo group, 
SIRT1 level did not change during the six-
week study period. Interestingly, based on 
GOLD criteria results, significantly 
elevated serum levels of SIRT1 in CLA 
supplementation group were only observed 
in stages III-IV. Yanagisawa et al. reported 
that protein levels of SIRT1 were 
significantly decreased in patients with 
COPD (Yanagisawa et al., 2017). It is also 
known that the protein levels of SIRT1 
were associated with the severity of the 
airways obstruction and have a strong 
negative correlation with the amount of 
cigarette consumption, suggesting that 
oxidative stress may lead to a decrease in 
SIRT1 levels (Kwon and Ott, 2008). 
Accordingly, SIRT1 levels may be an 
important factor in the estimation of some 
disease characteristic in patients with 
COPD such as emphysema. On the other 
hand, Kim et al. showed that CLA 
supplementation had significant effects on 
the increase of SIRT1 (Kim et al., 2016). 
Kim et al. demonstrated that CLA 
supplementation in wild-type male animals 
led to an increase in SIRT1 values (Kim et 
al., 2016). In addition, in an animal study 
conducted by Shen and colleagues, it was 
also found that CLA supplementation 
resulted in an increase in SIRT1 activity 
(Shen et al., 2018), which is consistent with 
the current study outcomes.  
Occurrence of inflammation in the 
respiratory system activates various types 
of cells, such as macrophages, neutrophils, 
eosinophils, and epithelial cells that leads to 
the production of reactive oxygen species 
(ROS) (Chun, 2015). Under conditions of 
high ROS production, cellular ROS-
induced damage occur as a result of redox 
imbalance (Yadav and Ramana, 2013). 
Various transcription factors such as 
activator protein-1 (AP-1) and NF-kB are 
activated as a result of redox activation and 
increase the production of pro-
inflammatory molecules. SIRT1 plays an 
important role in modulation of redox 
processes (Yadav and Ramana, 2013). It 
was shown that SIRT1 induces pulmonary 
protection against cellular inflammation in 
response to oxidative stress by regulating 
various cellular processes such as 
autophagy, apoptosis, and mitochondrial 
biogenesis (Yao and Rahman, 2011). 
Although the precise mechanism of SIRT1 
activity in patients with COPD is unclear, 
the increase in SIRT1 level as well as the 
improvement of pulmonary function and 
6MWD modification as a result of CLA 
intervention, may be related to these 
changes. Our results also showed a negative 
correlation between the SIRT1 and IL-6 
levels in the CLA supplementation group, 
markedly in stages III-IV of GOLD criteria. 
It may be deduced that in patients with 
CLA supplementation on IL-6 and sirtuin1 in COPD 
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COPD under intervention with CLA, 
various mechanisms can be activated, 
directly or indirectly, to improve 
pulmonary function and reduce 
inflammatory markers, which requires 
more investigation.  
This study demonstrated that CLA 
supplementation has anti-inflammatory 
effects mediated through suppression of IL-
6 production. CLA can modulate SIRT1 
levels in COPD patients. Supplementation 
with CLA can modify the inflammatory 
markers and improve the health status of 
COPD patients.  Evaluation of other 
inflammatory pathways involved in 
patients with COPD under CLA 
supplementation needs further studies to 
determine its efficacy. 
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